Journal of Clinical Sleep Medicine
March 1, 2016
Donna L Littlewood, Patricia A Gooding, Maria Panagioti et al.
Study objectives: Although nightmares appear to be related to suicidal behaviors, the mechanisms which underpin this relationship are unknown. We sought to address this gap by examining a multiple mediation hypothesis whereby nightmares were predicted to have an indirect effect on suicidal behaviors through perceptions of defeat, entrapment, and hopelessness. Methods: Data were collected from...
European Psychiatry
March 1, 2016
E. Silva, S. Simões, H. Espírito-Santo et al.
Introduction: Depression is one of the main causes of incapacity worldwide. Research has shown that mindfulness practice, self-compassion promotion, and spiritual well-being are beneficial for depressed individuals. Objective: Analyze the associations between compassion, mindfulness, and spiritual well-being, during and after a therapeutic intervention (concluded less than a year ago). Aims: To...
Brain and Behavior
March 2016
B Blair Braden, Teri B Pipe, Ryan Smith et al.
Mindfulness-based stress reduction (MBSR) reduces depression, anxiety, and pain for people suffering from a variety of illnesses, and there is a growing need to understand the neurobiological networks implicated in self-reported psychological change as a result of training. Combining complementary and alternative treatments such as MBSR with other therapies is helpful; however, the time...
BJPsych Open
March 1, 2016
Akshya Vasudev, Amanda Arena, A. Burhan et al.
Retracted
Late-life depression affects 2–6% of seniors aged 60 years and above. Patients are increasingly embracing non-pharmacological therapies, many of which have not been scientifically evaluated. This study aimed to evaluate a category of meditation, automatic self-transcending meditation (ASTM), in alleviating symptoms of depression when augmenting treatment as usual (NCT02149810). The preliminary...
The World Journal of Biological Psychiatry
February 26, 2016
Eric J Lenze, Nuri B Farber, E. Kharasch et al.
ABSTRACT Objectives We examined the feasibility of a high-dose, 96-h infusion of ketamine in treatment-resistant depression. Methods Ten participants were randomised to receive a 96-h ketamine infusion, titrated as tolerated to a target rate of 0.6 mg/kg/h, while 10 received a 40-min ketamine infusion (0.5 mg/kg). Both groups received clonidine, titrated to a maximum of 0.6 mg orally daily,...
Behavioural Brain Research
February 15, 2016
Lakshmi Rajagopal, Jeffrey S Burgdorf, Joseph R Moskal et al.
GLYX-13 (rapastinel), a tetrapeptide (Thr-Pro-Pro-Thr-amide), has been reported to have fast acting antidepressant properties in man based upon its N-methyl-D-aspartate receptor (NMDAR) glycine site functional partial agonism. Ketamine, a non-competitive NMDAR antagonist, also reported to have fast acting antidepressant properties, produces cognitive impairment in rodents and man, whereas...
Psychological Medicine
February 12, 2016
Taishiro Kishimoto, J. M. Chawla, K. Hagi et al.
363 citations
Background Ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists (NMDAR antagonists) recently demonstrated antidepressant efficacy for the treatment of refractory depression, but effect sizes, trajectories and possible class effects are unclear. Method We searched PubMed/PsycINFO/Web of Science/clinicaltrials.gov until 25 August 2015. Parallel-group or cross-over randomized...
Drug Discovery Today
February 6, 2016
Danielle M. Gerhard, Eric S. Wohleb, Ronald S. Duman
Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the...
The British Journal of Psychiatry
February 1, 2016
Robert A Schoevers, Tharcila V. Chaves, Sonya M. Balukova et al.
80 citations
BACKGROUND: Recent studies with intravenous (i.v.) application of ketamine show remarkable but short-term success in patients with MDD. Studies in patients with chronic pain have used different ketamine applications for longer time periods. This experience may be relevant for psychiatric indications. AIMS: To review the literature about the dosing regimen, duration, effects and side-effects of...
Journal of Affective Disorders
January 15, 2016
Megha M Vasavada, Amber M Leaver, Randall Espinoza et al.
58 citations
Ketamine elicits an acute antidepressant effect in patients with major depressive disorder (MDD). Here, we used diffusion imaging to explore whether regional differences in white matter microstructure prior to treatment may predict clinical response 24h following ketamine infusion in 10 MDD patients. FSL's Tract-Based Spatial Statistics (TBSS) established voxel-level differences in fractional...
BMC Medical Ethics
January 14, 2016
Melvyn W B Zhang, Keith M. Harris, Roger Ho
69 citations
BACKGROUND: Depressive disorders are a common form of psychiatric illness and cause significant disability. Regulation authorities, the medical profession and the public require high safety standards for antidepressants to protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen (phencyclidine). Its abuse is a major worldwide public...
The World Journal of Biological Psychiatry
January 11, 2016
Matthew N. Cooper, Joshua D. Rosenblat, Danielle S. Cha et al.
40 citations
Objectives Replicated evidence has demonstrated that ketamine exerts rapid-acting and potent antidepressant effects. Notwithstanding, its promise to mitigate depressive symptoms and suicidality in antidepressant-resistant populations, several limitations and safety concerns accompany ketamine including, but not limited to, the potential for abuse and psychotomimetic/dissociative experiences....
2016
Michael A. Cerullo, A. Stryker
In severe depression thoughts of suicide can develop over weeks or months. Traditional pharmacologic or psychotherapeutic treatments take several weeks before they begin to improve symptoms. This gradual improvement is consistent with our everyday experience of the self. However, a new treatment, ketamine, can alter depressive symptoms within hours or even minutes. Ketamine can stop suicidal...
Psychology Research and Behavior Management
2016
Meagan B. MacKenzie, Nancy L. Kocovski
Mindfulness-based cognitive therapy (MBCT) was developed as a psychological intervention for individuals at risk of depressive relapse. Possible mechanisms of change for this intervention are in line with its theoretical underpinnings, and include increases in mindfulness and/or decreases in negative repetitive thoughts. This review provides an overview of current trends in MBCT research,...
International Journal of Yoga
2016
Sonal Mathur, Mahendra Prakash Sharma, Srikala Bharath
Depression is the most common mental illness in the elderly, and cost-effective treatments are required. Therefore, this study is aimed at evaluating the effectiveness of a mindfulness-based cognitive therapy (MBCT) on depressive symptoms, mindfulness skills, acceptance, and quality of life across four domains in patients with late-onset depression. A single case design with pre- and...
Mindfulness
2016
Joanna Mann, Willem Kuyken, Heather O'Mahen et al.
Parental depression can adversely affect parenting and children's development. We adapted mindfulness-based cognitive therapy (MBCT) for parents (MBCT-P) with a history of depression and describe its development, feasibility, acceptability and preliminary estimates of efficacy. Manual development involved interviews with 12 parents who participated in MBCT groups or pilot MBCT-P groups. We...
Mindfulness
2016
Agna A. Bartels‐Velthuis, Maya J. Schroevers, Karen Van der Ploeg et al.
We developed a novel compassion-focused training (mindfulness-based compassionate living; MBCL) and examined its effects in a heterogeneous psychiatric outpatient population with regard to feasibility and changes in levels of depression, anxiety, mindfulness and compassion. The training consisted of nine weekly 2.5-h sessions. Thirty-three patients, who had followed a mindfulness-based stress...
Clinical practice and epidemiology in mental health : CP & EMH
2016
Tonny Elmose Andersen, Henrik Bjarke Vægter
Eradication of pain is seldom an option in chronic pain management. Hence, mindfulness meditation has become popular in pain management. This pilot study compared the effect of a 13-weeks cognitive behavioural therapy program with integrated mindfulness meditation (CBTm) in patients with chronic non-malignant pain with a control condition. It was hypothesised that the CBTm program would reduce...
The Brown University Psychopharmacology Update
2016
A review and meta‐analysis of the effects of N‐methyl‐D‐aspartate (NMDA) receptor antagonists in treating major depression has confirmed that ketamine is the only such drug to date that has demonstrated antidepressant efficacy across multiple trials. Authors of the review stated, however, that the findings regarding ketamine should be viewed with caution because the beneficial effects are not...
PeerJ
2016
Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...